GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function
- 1Clinic of Dermatovenereology, University Medical Centre Ljubljana, Gradiškova
- 2University of Ljubljana, Faculty of Medicine, Vrazov trg
- 3Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Zaloška
Abstract
Obesity and lymphedema are linked through increased interstitial fluid load, impaired collecting-vessel pumping, inflammation, and progressive fibro-adipose remodeling. This bidirectional relationship makes glucagon-like peptide-1 receptor agonists (GLP-1RAs) relevant through two potentially distinct pathways. First, substantial weight loss may unload a compromised lymphatic system, improve mobility, and reduce adipose-driven inflammation. Second, GLP-1 signaling may directly influence lymphatic vessel function. Case reports and a retrospective cohort have described reduced limb volume, improved symptoms or imaging findings, and a lower incidence of breast cancer-related lymphedema among GLP-1RA users. Experimental work has identified GLP-1 receptors in lymphatic endothelial cells and shown that pharmacological activation with semaglutide increases the pumping capacity of isolated collecting lymphatic vessels. These findings support a potential direct lymphatic effect but do not establish clinical efficacy in human lymphedema. Improvement during treatment may instead reflect reduced fat mass, greater mobility, or changes in conventional care. Future studies should distinguish weight-loss-dependent unloading from weight-loss-independent effects by combining standardized clinical outcomes, functional imaging, body-composition measurements, and, where feasible, weight-matched comparison groups. The available evidence therefore supports prospective investigation rather than clinical adoption. Trials should assess early vascular responses before major weight loss, longer-term changes in tissue composition and inflammation, and durability after treatment withdrawal, while maintaining standardized compression, exercise, skin care, and other components of established lymphedema management throughout. Until such evidence is available, GLP-1RAs should be prescribed for established metabolic indications rather than lymphedema itself, and any lymphatic benefit should be regarded as a promising clinical signal rather than a treatment claim.
Related
- Pixel-Level Quantification of Subcutaneous Shear-Wave Velocity Heterogeneity for Grading Lymphatic Obstruction in Breast Cancer-Related Lymphedema
- Potential synergy between GLP-1 receptor agonists and follicle-stimulating hormone in improving spermatogenesis: biological rationale and future directions
- Therapeutic potential of metabotropic glutamate receptor 7 modulation in correcting cognitive deficits of schizophrenia
- Cholesterol-Mediated Modulation of Collecting Lymphatic Vessel Contractility: Exploring Cholesterol Depletion as a Therapeutic Alternative to Improve Lymphatic Function in Hypercholesterolemia
- Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
BibTeX
@article{sabovic2026glp1,
title = {{GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function}},
author = {Eva Klara Merzel Šabović and Miodrag Janić and Tanja Planinšek Ručigaj},
journal = {Frontiers in Endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1980239},
url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1980239/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function
AU - Eva Klara Merzel Šabović
AU - Miodrag Janić
AU - Tanja Planinšek Ručigaj
PY - 2026
DA - 2026/10/08
JO - Frontiers in Endocrinology
DO - 10.3389/fendo.2026.1980239
UR - https://www.frontiersin.org/articles/10.3389/fendo.2026.1980239/full
AB - Obesity and lymphedema are linked through increased interstitial fluid load, impaired collecting-vessel pumping, inflammation, and progressive fibro-adipose remodeling. This bidirectional relationship makes glucagon-like peptide-1 receptor agonists (GLP-1RAs) relevant through two potentially distinct pathways. First, substantial weight loss may unload a compromised lymphatic system, improve mobility, and reduce adipose-driven inflammation. Second, GLP-1 signaling may directly influence lymphatic vessel function. Case reports and a retrospective cohort have described reduced limb volume, improved symptoms or imaging findings, and a lower incidence of breast cancer-related lymphedema among GLP-1RA users. Experimental work has identified GLP-1 receptors in lymphatic endothelial cells and shown that pharmacological activation with semaglutide increases the pumping capacity of isolated collecting lymphatic vessels. These findings support a potential direct lymphatic effect but do not establish clinical efficacy in human lymphedema. Improvement during treatment may instead reflect reduced fat mass, greater mobility, or changes in conventional care. Future studies should distinguish weight-loss-dependent unloading from weight-loss-independent effects by combining standardized clinical outcomes, functional imaging, body-composition measurements, and, where feasible, weight-matched comparison groups. The available evidence therefore supports prospective investigation rather than clinical adoption. Trials should assess early vascular responses before major weight loss, longer-term changes in tissue composition and inflammation, and durability after treatment withdrawal, while maintaining standardized compression, exercise, skin care, and other components of established lymphedema management throughout. Until such evidence is available, GLP-1RAs should be prescribed for established metabolic indications rather than lymphedema itself, and any lymphatic benefit should be regarded as a promising clinical signal rather than a treatment claim.
SN - 1664-2392
ER -